Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial

Ynke Larivière, Trésor Zola Matuvanga, Bernard Isekah Osang’ir, Solange Milolo, Rachel Meta, Primo Kimbulu, Cynthia Robinson, Michael Katwere, Chelsea McLean, Gwen Lemey, Junior Matangila, Vivi Maketa, Patrick Mitashi, Jean‐Pierre Van Geertruyden, Pierre Van Damme, Hypolite Muhindo Mavoko